Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/24/2025

SNRI as Adjunct Therapy for Anxiety

Primary Role: Monotherapy, Not Adjunct

  • The American Academy of Child and Adolescent Psychiatry recommends SNRIs as a class that significantly improve clinician-reported primary anxiety symptoms compared to placebo (high strength of evidence), based on 4 RCTs including 911 patients ages 6-18 years 2, 3
  • SNRIs demonstrate comparable efficacy to SSRIs for anxiety disorders, with similar response rates (NNT = 4.94 for SNRIs vs 4.70 for SSRIs) and comparable dropout rates to placebo 4

Available SNRI Medications

  • The American Academy of Child and Adolescent Psychiatry states that the SNRI class includes four medications currently marketed in the United States, including Venlafaxine (immediate and extended release formulations) 5, 6, 7

Mechanism Supporting Efficacy

  • SNRIs inhibit presynaptic reuptake of both norepinephrine and serotonin, which paradoxically reduces anxiety despite norepinephrine's association with the "fight or flight" stress response, likely through complex neurotransmitter interactions 5, 6

Dosing Considerations

  • Extended-release formulations allow once-daily dosing, including Venlafaxine extended release, desvenlafaxine, and duloxetine, which have sufficiently long elimination half-lives for single daily dosing 5, 7

Critical Safety Considerations

  • Monitor blood pressure and pulse regularly, as SNRIs are associated with sustained hypertension, increased blood pressure, and increased pulse 1, 8
  • SNRIs increase bleeding risk, particularly when combined with NSAIDs, aspirin, warfarin, or other anticoagulants 8

Common Adverse Effects

  • Compared to placebo, SNRIs are associated with increased fatigue/somnolence (moderate strength of evidence) 1, 2
  • Additional common effects include diaphoresis, dry mouth, abdominal discomfort, nausea, vomiting, diarrhea, dizziness, headache, tremor, insomnia, decreased appetite, and weight loss 1, 7, 8

Discontinuation Syndrome

  • SNRIs require slow taper upon discontinuation—never stop abruptly, as venlafaxine is particularly associated with discontinuation symptoms 4, 7
  • Both venlafaxine and desvenlafaxine are associated with overdose fatalities 6, 8

REFERENCES